Published in Infect Immun on December 01, 1991
Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun (1992) 1.45
Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci U S A (1999) 1.34
Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun (1992) 1.23
Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls. Infect Immun (1996) 1.17
Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol (2013) 1.13
Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun (1996) 1.00
A scalable method for O-antigen purification applied to various Salmonella serovars. Anal Biochem (2012) 0.97
Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Infect Immun (2001) 0.97
Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun (2000) 0.96
Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination. Clin Diagn Lab Immunol (1996) 0.96
Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proc Natl Acad Sci U S A (2007) 0.95
Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect Immun (1993) 0.95
O:2-CRM(197) conjugates against Salmonella Paratyphi A. PLoS One (2012) 0.93
Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component. Proc Natl Acad Sci U S A (2008) 0.92
Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes. Infect Immun (1995) 0.89
Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice. Infect Immun (2000) 0.85
Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1. Infect Immun (1997) 0.84
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. Hum Vaccin Immunother (2015) 0.84
Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid. Infect Immun (1994) 0.81
Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice. Infect Immun (1999) 0.81
Simplest identification, O-specific polysaccharide purification and antigenic evaluation of Salmonella enterica serovar Typhi Vi negative isolate. EXCLI J (2015) 0.79
Convergent synthesis of a common pentasaccharide corresponding to the O-antigen of Escherichia coli O168 and Shigella dysenteriae type 4. Glycoconj J (2010) 0.79
Synthesis and antigenicity of BBGL-2 glycolipids of Borrelia burgdorferi, the causative agent of Lyme disease. Carbohydr Res (2011) 0.78
Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine. Proc Natl Acad Sci U S A (2011) 0.78
Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length. Glycoconj J (2013) 0.76
Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites. Sci Rep (2016) 0.76
Purification and antigenic detection of O-specific polysaccharides of Salmonella enterica serovar Paratyphi A isolate from Pakistan: an emerging threat. Springerplus (2016) 0.75
Immunogenicity comparison of conjugate vaccines composed of alginate and lipopolysaccharide of Pseudomonas aeruginosa bound to diphtheria toxoid. Iran J Microbiol (2014) 0.75
Tissue sulfhydryl groups. Arch Biochem Biophys (1959) 61.89
The thiobarbituric acid assay of sialic acids. J Biol Chem (1959) 43.78
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J (1978) 5.40
Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull World Health Organ (1965) 4.37
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Impact in the United States of the Shiga dysentery pandemic of Central America and Mexico: a review of surveillance data through 1972. J Infect Dis (1974) 2.91
Impairment of the immune response to vaccination after acute malaria. Lancet (1978) 2.39
Epidemic bacillary dysentery in West Bengal, India, 1984. Lancet (1984) 2.38
Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol (1966) 2.23
An outbreak of dysentery caused by Shigella dysenteriae type 1 on a coral island in the Bay of Bengal. J Infect Dis (1975) 2.15
Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun (1983) 2.10
A small plasmid in Shigella dysenteriae 1 specifies one or more functions essential for O antigen production and bacterial virulence. Infect Immun (1984) 1.77
Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol (1991) 1.73
Clinical and microbiologic features of Shigella and enteroinvasive Escherichia coli infections detected by DNA hybridization. J Clin Microbiol (1988) 1.57
Haemolytic-uraemic syndrome complicating shigella dystentery in south Indian children. Br Med J (1978) 1.56
Serum factors responsible for killing of Shigella. Immunology (1974) 1.56
Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med (1987) 1.56
Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med (1990) 1.45
An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides. J Immunol Methods (1985) 1.44
Changing pattern of resistant Shiga bacillus (Shigella dysenteriae type 1) and Shigella flexneri in Bangladesh. J Infect Dis (1985) 1.43
Structural studies of Shigella flexneri O-antigens. Eur J Biochem (1978) 1.43
Genetic and biochemical analysis of Shigella dysenteriae 1 O antigen polysaccharide biosynthesis in Escherichia coli K-12: structure and functions of the rfb gene cluster. Microb Pathog (1986) 1.42
Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet (1986) 1.42
Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis. Infect Immun (1984) 1.42
Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. Infect Immun (1981) 1.38
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest (1987) 1.33
Small virulence plasmid of Shigella dysenteriae 1 strain W30864 encodes a 41,000-dalton protein involved in formation of specific lipopolysaccharide side chains of serotype 1 isolates. Infect Immun (1984) 1.14
Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J Pediatr (1988) 1.14
The processing and collaborative assay of a reference endotoxin. J Biol Stand (1983) 1.14
Improved procedures for the conjugation of oligosaccharides to protein by reductive amination. Can J Biochem Cell Biol (1984) 1.12
Somatic antigens of shigella. Structural investigation on the O-specific polysaccharide chain of Shigella dysenteriae type 1 lipopolysaccharide. Eur J Biochem (1976) 1.09
'O'-antigens are essential virulence factors of Shigella sonnei and Shigella dysenteriae 1. Zentralbl Bakteriol Mikrobiol Hyg B (1985) 1.04
Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. J Biol Stand (1989) 1.04
Expression of lipopolysaccharide O antigen in Escherichia coli K-12 hybrids containing plasmid and chromosomal genes from Shigella dysenteriae 1. Infect Immun (1984) 1.03
Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates. Infect Immun (1991) 1.00
Synthesis of immunogenic oligosaccharide-protein conjugates from the lipopolysaccharide of Neisseria gonorrhoeae P9. J Immunol Methods (1982) 0.99
The humoral antibody response to Shigella dysenteriae type 1 infection, as determined by ELISA. Bull World Health Organ (1984) 0.99
Shigella dysenteriae type 1 infections in US travellers to Mexico, 1988. Lancet (1989) 0.96
Immunization with Shigella dysenteriae type 1: evaluation of antitoxic immunity in prevention of experimental disease in rhesus monkeys (Macaca mulatta). J Infect Dis (1977) 0.95
Shigella vaccines. Rev Infect Dis (1989) 0.81
Studies with Shigella dysenteriae (Shiga) infection and intoxication in Macacus mulatta monkeys. J Infect Dis (1950) 0.81
Detection of blood group A-like substance in bacterial and viral vaccines by countercurrent immunoelectrophoresis using Helix pomatia lectin. J Biol Stand (1984) 0.80
STUDIES OF DIARRHEAL DISEASE IN CENTRAL AMERICA. VI. AN EPIDEMIC OF DIARRHEA IN A GUATEMALAN HIGHLAND VILLAGE, WITH A COMPONENT DUE TO SHIGELLA DYSENTERIAE, TYPE 1. Am J Trop Med Hyg (1965) 0.80
Multiply drug-resistant Shigella dysenteriae type 1 and travelers' diarrhea. J Infect Dis (1986) 0.77
Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol (1991) 11.09
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med (1994) 7.05
Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet (1975) 6.25
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Negative affectivity: the disposition to experience aversive emotional states. Psychol Bull (1984) 5.93
Toward a consensual structure of mood. Psychol Bull (1985) 5.58
Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 5.32
Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol (1985) 4.88
Health complaints, stress, and distress: exploring the central role of negative affectivity. Psychol Rev (1989) 4.72
Comorbidity of anxiety and unipolar mood disorders. Annu Rev Psychol (1998) 4.71
Temperament, personality, and the mood and anxiety disorders. J Abnorm Psychol (1994) 4.70
A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol Metab (1971) 4.38
A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet (1996) 4.30
Characterization of the imitation switch subfamily of ATP-dependent chromatin-remodeling factors in Saccharomyces cerevisiae. Genes Dev (1999) 4.25
Serum IgM and IgG responses in postnatally acquired rubella. Lancet (1969) 4.16
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis (1984) 4.10
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med (2001) 4.08
Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res (1973) 3.89
Public confidence and cardiac surgical outcome. Cardiac surgery: the fall guy in medical quality assurance. BMJ (1998) 3.77
Measurement of social-evaluative anxiety. J Consult Clin Psychol (1969) 3.72
"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet (1997) 3.68
A gamma-ray burst at a redshift of z approximately 8.2. Nature (2009) 3.29
Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis (1995) 3.25
Positive and negative affectivity and their relation to anxiety and depressive disorders. J Abnorm Psychol (1988) 3.19
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol (1985) 2.97
Lipid on capsular polysaccharides of gram-negative bacteria. J Biol Chem (1981) 2.91
Frequency of E. coli K antigens in urinary-tract infections in children. Lancet (1977) 2.89
Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med (1979) 2.89
Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. Lancet (1971) 2.84
Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab (1973) 2.77
Use of antiserum agar for detection of Haemophilus influenzae type b in the pharynx. Pediatr Res (1975) 2.74
Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis (1990) 2.72
Intra-abdominal and gastrointestinal tuberculosis. Colorectal Dis (2007) 2.70
Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet (1974) 2.67
Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry (1978) 2.65
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet (1987) 2.59
Comparative analysis of plasmids and some metabolic characteristics of Escherichia coli K1 from diseased and healthy individuals. Infect Immun (1980) 2.59
Measurement of Pseudomonas aeruginosa phenazine pigments in sputum and assessment of their contribution to sputum sol toxicity for respiratory epithelium. Infect Immun (1988) 2.56
The isolation and biologic activities of purified secretory IgA and IgG anti-Salmonella typhimurium "O" antibodies from rabbit intestinal fluid and colostrum. J Immunol (1971) 2.54
Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun (1972) 2.47
Serogroup identification of Neisseria meningitidis: comparison of an antiserum agar method with bacterial slide agglutination. J Clin Microbiol (1978) 2.44
Mortality and utilisation of critical care resources amongst high-risk surgical patients in a large NHS trust. Anaesthesia (2008) 2.42
Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest (1987) 2.40
Pathogenesis of neonatal Escherichia coli meningitis: induction of bacteremia and meningitis in infant rats fed E. coli K1. Infect Immun (1977) 2.39
Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun (1988) 2.36
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med (1999) 2.33
The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg (2000) 2.29
Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum (1967) 2.23
Differential complement resistance mediates virulence of Haemophilus influenzae type b. Infect Immun (1982) 2.23
Is there a Persian Gulf War syndrome? Evidence from a large population-based survey of veterans and nondeployed controls. Am J Med (2000) 2.23
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice. Eur J Anaesthesiol (2007) 2.19
Production of monovalent antisera by induction of immunological tolerance for capsular typing of Streptococcus pneumoniae. FEMS Microbiol Lett (1992) 2.19
Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis (1984) 2.17
Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med (1975) 2.16
Gamma-A-immunoglobulin from rabbit colostrum. J Immunol (1966) 2.16
Molecular cloning of the K1 capsular polysaccharide genes of E. coli. Nature (1981) 2.15
Clinical, bacteriological, and immunological characterisation of ampicillin-resistant Haemophilus influenzae type B. Lancet (1974) 2.14
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand (1977) 2.11
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
Diagnosis and classification of psychopathology: challenges to the current system and future directions. Annu Rev Psychol (1995) 2.11
In situ bioreduction of technetium and uranium in a nitrate-contaminated aquifer. Environ Sci Technol (2004) 2.11
Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun (1983) 2.10
Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis (2000) 2.04
Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption. Relationship to outcome. Chest (1993) 2.01
Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine. Nat New Biol (1971) 1.98
A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli. Pediatr Res (1976) 1.96
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
Manipulating hemodynamics and oxygen transport in critically ill patients. N Engl J Med (1995) 1.91
Safety and efficacy of postoperative epidural analgesia. Br J Anaesth (2001) 1.90
Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Biotechnology (N Y) (1994) 1.87
Serum Copper Levels in Pregnancy and Pre-Eclampsia. J Clin Pathol (1949) 1.85
Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis (1977) 1.84
Biochemical quantification of DNA in human articular and septal cartilage using PicoGreen and Hoechst 33258. Osteoarthritis Cartilage (2002) 1.84